Schizoaffective Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Schizoaffective Disorder

MalaCards integrated aliases for Schizoaffective Disorder:

Name: Schizoaffective Disorder 12 73 43 54 15 17 70
Schizophreniform Psychosis, Affective Type 43
Schizophrenia, Schizo-Affective Type 43
Schizo-Affective Type Schizophrenia 43
Schizoaffective Schizophrenia 43
Schizo-Affective Psychosis 43
Schizoaffective Psychosis 43


External Ids:

Disease Ontology 12 DOID:5418
ICD9CM 34 295.7
MeSH 44 D011618
NCIt 50 C94378
SNOMED-CT 67 231490005
ICD10 32 F25 F25.9
UMLS 70 C0036337

Summaries for Schizoaffective Disorder

MedlinePlus Genetics : 43 Schizoaffective disorder is a mental health condition that includes features of both schizophrenia and a mood disorder such as bipolar disorder or depression. The prefix "schizo-" refers to the psychotic symptoms of schizophrenia that affect a person's thinking, sense of self, and perceptions. The term "-affective" refers to extreme shifts in mood, energy, and behavior.Schizoaffective disorder has a wide range of signs and symptoms that make it challenging to diagnose. Its features overlap significantly with those of schizophrenia and bipolar disorder, and there is debate about whether schizoaffective disorder should be considered a separate diagnosis or a subtype of one of these other conditions.Signs and symptoms of psychosis in people with schizoaffective disorder include false perceptions called hallucinations, such as hearing voices no one else can hear or experiencing visions, smells, or tactile (touch) sensations. Strongly held false beliefs (delusions) are also a characteristic feature. For example, affected individuals may be certain that they are a particular historical figure or that they are being plotted against or controlled by others.There are two major types of schizoaffective disorder, based on which mood disorder is involved: the bipolar type and the depressive type. The bipolar type includes both dramatic "highs," called manic episodes, and "lows," called depressive episodes. The depressive type includes only depressive episodes. Manic episodes are characterized by increased energy and activity, irritability, restlessness, an inability to sleep, and reckless behavior. Depressive episodes are marked by low energy and activity, a feeling of hopelessness, and an inability to perform everyday tasks.The psychosis and mood problems associated with schizoaffective disorder usually become evident in adolescence or young adulthood. People with this condition often have difficulty functioning at school, at work, and in social settings. Disordered thinking and concentration, inappropriate emotional responses, erratic speech and behavior, and difficulty with personal hygiene and everyday tasks are also common. People with schizoaffective disorder have a higher risk of substance abuse problems and dying by suicide than the general population.

MalaCards based summary : Schizoaffective Disorder, also known as schizophreniform psychosis, affective type, is related to schizophrenia 9 and schizophrenia 18. An important gene associated with Schizoaffective Disorder is DISC2 (Disrupted In Schizophrenia 2), and among its related pathways/superpathways are Neuroscience and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Sibutramine and Lorazepam have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A psychotic disorder that is characterized by recurring episodes of mood fluctuations and a loss of contact with reality.

Wikipedia : 73 Schizoaffective disorder (SZA, SZD or SAD) is a mental disorder characterized by abnormal thought... more...

Related Diseases for Schizoaffective Disorder

Diseases related to Schizoaffective Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 9 32.1 PRODH DISC1
2 schizophrenia 18 32.1 SLC1A1 PRODH NRXN1
3 schizophrenia 4 31.9 SLC1A1 PRODH
4 schizophrenia 2 31.5 PRODH DISC2 DISC1
5 depression 31.0 SLC6A4 PRL HTR2A HTR1A DISC2 BDNF
6 tardive dyskinesia 30.9 HTR2A DRD3 DRD2 COMT
7 hyperprolactinemia 30.7 PRL HTR2A DRD2
8 neuroleptic malignant syndrome 30.7 HTR2A HTR1A DRD2
9 movement disease 30.6 PRODH HTR1A DRD3 DRD2 COMT BDNF
10 post-traumatic stress disorder 30.5 SLC6A4 HTR2A DRD2 COMT BDNF
11 galactorrhea 30.5 PRL DRD2
12 sexual disorder 30.4 SLC6A4 PRL HTR2A HTR1A BDNF
13 mental depression 30.4 SLC6A4 PRODH HTR2A HTR1A DRD2 DISC1
14 endogenous depression 30.4 SLC6A4 PRL HTR2A HTR1A DRD2 COMT
15 schizophrenia 1 30.3 PRODH DTNBP1 DISC1
16 digeorge syndrome 30.3 PRODH NRXN1 DISC1 COMT
17 acute stress disorder 30.3 SLC6A4 HTR1A BDNF
18 conversion disorder 30.3 HTR2A COMT BDNF
19 personality disorder 30.2 SLC6A4 PRL HTR2A HTR1A DRD3 DRD2
20 bipolar i disorder 30.2 SLC6A4 HTR2A HTR1A DTNBP1 DRD2 COMT
21 dissociative disorder 30.2 SLC6A4 BDNF
22 delusional disorder 30.2 PRODH HTR2A HTR1A DRD3 DRD2 DISC1
23 speech and communication disorders 30.2 PRODH NRXN1 COMT BDNF
24 substance abuse 30.1 SLC6A4 PRODH PRL HTR2A HTR1A DRD3
25 opiate dependence 30.1 SLC6A4 DRD3 DRD2
26 dystonia 30.1 PRL HTR2A DRD3 DRD2 COMT BDNF
27 obsessive-compulsive disorder 30.1 SLC6A4 SLC1A1 PRL HTR2A HTR1A DRD3
28 conduct disorder 30.0 SLC6A4 DRD2 COMT
29 borderline personality disorder 30.0 SLC6A4 PRL HTR2A HTR1A DRD2 COMT
30 obsessive-compulsive personality disorder 30.0 SLC6A4 HTR2A DRD3 COMT
31 tobacco addiction 29.9 SLC6A4 NRXN1 HTR2A DRD3 DRD2 COMT
32 paranoid schizophrenia 29.9 SLC6A4 PRL NRXN1 HTR2A HTR1A DISC1
33 adjustment disorder 29.9 SLC6A4 HTR2A HTR1A BDNF
34 pathological gambling 29.9 SLC6A4 HTR2A HTR1A DRD3 DRD2 COMT
35 fragile x syndrome 29.9 SLC6A4 PRODH NRXN1 DISC1 BDNF
36 schizophreniform disorder 29.9 PRODH PRL NRXN1 HTR2A DTNBP1 DRD2
37 body mass index quantitative trait locus 11 29.8 PRODH NRXN1 HTR2A HTR1A DRD2 COMT
38 mood disorder 29.8 SLC6A4 PRODH HTR2A HTR1A DRD3 DRD2
39 alcohol dependence 29.8 SLC6A4 HTR2A HTR1A GABRB1 DRD3 DRD2
40 neurotic disorder 29.8 SLC6A4 HTR2A HTR1A COMT BDNF
41 cocaine dependence 29.8 SLC6A4 HTR2A DRD3 DRD2 COMT BDNF
42 alcohol use disorder 29.7 SLC6A4 PRODH HTR2A HTR1A DRD3 DRD2
43 anorexia nervosa 29.6 SLC6A4 PRL HTR2A HTR1A COMT BDNF
44 pervasive developmental disorder 29.6 SLC6A4 PRODH NRXN1 HTR2A DRD2 DISC1
45 anxiety 29.6 SLC6A4 SLC1A1 PRODH PRL HTR2A HTR1A
46 panic disorder 29.5 SLC6A4 PRL HTR2A HTR1A DRD3 DRD2
47 schizophrenia 29.5 SULT4A1 SLC6A4 SLC1A1 RGS4 PRODH PRL
48 psychotic disorder 29.4 SLC6A4 SLC1A1 RGS4 PRODH PRL NRXN1
49 social phobia 29.4 SLC6A4 PRODH PRL HTR2A HTR1A DRD2
50 migraine with or without aura 1 29.4 SLC6A4 PRL HTR2A HTR1A DRD3 DRD2

Graphical network of the top 20 diseases related to Schizoaffective Disorder:

Diseases related to Schizoaffective Disorder

Symptoms & Phenotypes for Schizoaffective Disorder

MGI Mouse Phenotypes related to Schizoaffective Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.19 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
2 homeostasis/metabolism MP:0005376 9.83 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
3 endocrine/exocrine gland MP:0005379 9.81 BDNF COMT DRD2 GABRB1 HTR2A NRXN1
4 nervous system MP:0003631 9.53 BDNF COMT DISC1 DRD2 DRD3 DTNBP1

Drugs & Therapeutics for Schizoaffective Disorder

Drugs for Schizoaffective Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
Lorazepam Approved Phase 4 846-49-1 3958
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Pravastatin Approved Phase 4 81093-37-0 54687
Ziprasidone Approved Phase 4 146939-27-7 60854
Ethanol Approved Phase 4 64-17-5 702
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
Haloperidol Approved Phase 4 52-86-8 3559
Galantamine Approved Phase 4 357-70-0 9651
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Iloperidone Approved Phase 4 133454-47-4 71360
Nicotine Approved Phase 4 54-11-5 942 89594
Amantadine Approved Phase 4 768-94-5 2130
Clozapine Approved Phase 4 5786-21-0 2818
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
21 Antidepressive Agents Phase 4
22 Quetiapine Fumarate Phase 4 111974-72-2
23 Dopamine Antagonists Phase 4
24 Anti-Obesity Agents Phase 4
25 Appetite Depressants Phase 4
26 Paliperidone Palmitate Phase 4
27 Anticonvulsants Phase 4
28 Serotonin 5-HT1 Receptor Agonists Phase 4
29 Serotonin Receptor Agonists Phase 4
30 Dopamine agonists Phase 4
31 Adrenergic Agents Phase 4
32 insulin Phase 4
33 Insulin, Globin Zinc Phase 4
34 Haloperidol decanoate Phase 4
35 Nootropic Agents Phase 4
36 Cholinesterase Inhibitors Phase 4
37 Atomoxetine Hydrochloride Phase 4
38 Pharmaceutical Solutions Phase 4
39 Incretins Phase 4
40 Liver Extracts Phase 4
41 Dopamine Agents Phase 4
42 Analgesics Phase 4
43 Cholinergic Agents Phase 4
44 Nicotinic Agonists Phase 4
45 Anti-Infective Agents Phase 4
46 Analgesics, Non-Narcotic Phase 4
47 Antiviral Agents Phase 4
48 Antiparkinson Agents Phase 4
Pramipexole Approved, Investigational Phase 3 104632-26-0 59868 119570
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
2 Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
3 The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
4 A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine Completed NCT00378183 Phase 4 risperidone
5 A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Adjunctive Treatment With Pravastatin in Partially Remitted Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00177580 Phase 4 Pravastatin
6 Biomarker Study of Acamprosate in Schizophrenia Completed NCT00688324 Phase 4 Acamprosate
7 High Dose Risperidone Consta for Patients With Schizophrenia With Unsatisfactory Response to Standard Dose Risperidone or Long-Acting Injectable Completed NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
8 Enhancing Adherence and Outcomes in Bipolar Disorder With Abilify Maintena + a Targeted Behavioral Approach to Promote Sustained Adherence and Behavioral Change Completed NCT03408873 Phase 4 Abilify Maintena
9 Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial Completed NCT00224315 Phase 4 ziprasidone;risperidone
10 CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia Completed NCT00007774 Phase 4 Haloperidol;Olanzapine
11 A Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder Completed NCT00649064 Phase 4 Ziprasidone
12 Effect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00373672 Phase 4 armodafinil (Nuvigil);placebo
13 A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy. Completed NCT00325689 Phase 4 Quetiapine or Risperidone + Aripiprazole;Quetiapine or Risperidone + placebo
14 Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00320736 Phase 4 galantamine
15 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? Completed NCT00306475 Phase 4 divalproex sodium ER;placebo
16 A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
17 A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder Completed NCT00406315 Phase 4 ziprasidone
18 A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00236379 Phase 4 Olanzapine;Risperidone
19 A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00222794 Phase 4 Atomoxetine (Strattera)
20 A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder Completed NCT00061802 Phase 4 risperidone, quetiapine
21 Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder. Completed NCT00304655 Phase 4 Aripiprazole
22 A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
23 The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00090012 Phase 4 Olanzapine;Quetiapine
24 The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy Completed NCT00485823 Phase 4 Olanzapine Hydrochloride
25 Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT01198353 Phase 4 Ziprasidone
26 Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone Completed NCT00190749 Phase 4 olanzapine;risperidone
27 Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder Completed NCT00100776 Phase 4 Olanzapine
28 A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adult Subjects With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic (Aripiprazole, Olanzapine, Quetiapine, or Risperidone) Completed NCT03568500 Phase 4 Aripiprazole;Olanzapine;Quetiapine;Risperidone
29 An Open-Label Study Changing Generic Clozapine Formulation to FazaClo® (Clozapine, USP) Orally Disintegrating Tablets in Stable Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00501618 Phase 4 Fazaclo
30 Ziprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study Completed NCT00650429 Phase 4 Ziprasidone
31 A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder Completed NCT00845507 Phase 4 Exenatide;Placebo
32 A Multi-center, Randomized, Double Blind, Parallel, PhaseⅣ Trial to Evaluate the Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder Completed NCT02137993 Phase 4 A-prexa;Zyprexa
33 A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
34 A Four-Week Double Blind Multicenter Study Comparing The Efficacy And Safety Of Ziprasidone To Aripiprazole In Subjects With Schizophrenia Or Schizoaffective Disorder Needing Inpatient Care Completed NCT00634348 Phase 4 Aripiprazole;Ziprasidone
35 A Single-arm Evaluation of the Safety of Paliperidone Extended-Release (ER) in Subjects With Schizophrenia or Schizoaffective Disorder With Hepatic Disease Completed NCT00535145 Phase 4 Treatment as usual (TAU), Paliperidone ER
36 Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone Completed NCT01855074 Phase 4 Risperidone
37 A Comparison of Risperidone and Haloperidol for Prevention of Relapse in Subjects With Schizophrenia and Schizoaffective Disorders Completed NCT00253110 Phase 4 risperidone;haloperidol
38 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
39 Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres Completed NCT00526877 Phase 4 Risperidone
40 An Exploratory Study to Assess the Effects of Fanapt® on Social Cognitive Performance Terminated NCT01929889 Phase 4 Iloperidone
41 Metformin and Lorcaserin for Weight Loss in Schizophrenia Terminated NCT02796144 Phase 4 Lorcaserin;Metformin;Placebo
42 Amantadine Addition to Paliperidone ER or Risperidone Consta Therapy for Prolactin Elevation Terminated NCT00975611 Phase 4 Amantadine Hydrochloride, USP;Amantadine Hydrochloride, USP;Placebo
43 High-Dose Versus Regular-Dose Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder Terminated NCT00046813 Phase 4 Nicotine patch
44 A Comparison Of The Effects Of Added Metformin (Versus No Added Metformin) On Psychopathology, Lipids, And Measures of Inflammation During The Initiation Or Re-Institution Of Treatment With Clozapine In Patients With Schizophrenia Or Schizoaffective Disorder Terminated NCT02140788 Phase 4 Metformin;Fish Oil
45 Combined Treatment of Cardiovascular Risk Factors In Newly Admitted Patients With Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine And Matched Controls Withdrawn NCT00672464 Phase 4 Olanzapine;Metformin;Simvastatin
46 A Randomized Trial Administering Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffective Disorder Unknown status NCT01320982 Phase 3 minocycline;pramipexole;acetylsalicylic acid;placebo
47 A Randomized Trial Administering Raloxifene vs Placebo as add-on to Antipsychotics in Post Menopausal Patients With Schizophrenia or Schizoaffective Disorder Unknown status NCT01280305 Phase 3 raloxifene;placebo
48 A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder Completed NCT00297947 Phase 2, Phase 3 quetiapine;quetiapine
49 Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85. Completed NCT00495118 Phase 3 risperidone
50 Motivational Interviewing to Improve Work Outcomes in Schizophrenia Completed NCT00261716 Phase 3

Search NIH Clinical Center for Schizoaffective Disorder

Genetic Tests for Schizoaffective Disorder

Anatomical Context for Schizoaffective Disorder

MalaCards organs/tissues related to Schizoaffective Disorder:

Brain, Cortex, Eye, Prefrontal Cortex, Pituitary, Liver, Temporal Lobe

Publications for Schizoaffective Disorder

Articles related to Schizoaffective Disorder:

(show top 50) (show all 4373)
# Title Authors PMID Year
Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients. 61 54
20521326 2010
Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. 61 54
19551763 2009
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. 54 61
19336781 2009
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. 61 54
19200422 2009
Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. 61 54
19142110 2009
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. 54 61
18786813 2008
Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. 54 61
18628679 2008
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. 61 54
18320559 2008
Does diagnostic classification of early-onset psychosis change over follow-up? 54 61
17665305 2008
Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia. 61 54
17504246 2008
Dysbindin gene variants are associated with bipolar I disorder in a Korean population. 61 54
17433541 2007
The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. 54 61
17267179 2007
The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. 61 54
16478753 2006
COMT genotype and manic symptoms in schizophrenia. 61 54
16828262 2006
BDNF gene variants and brain morphology in schizophrenia. 54 61
16741916 2006
Hyperprolinemia is not associated with childhood onset schizophrenia. 61 54
16389584 2006
Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. 61 54
16380905 2005
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. 61 54
16232322 2005
Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. 54 61
16203953 2005
A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. 61 54
15940305 2005
DISC1 and neurocognitive function in schizophrenia. 61 54
16056147 2005
Hyperprolinemia is a risk factor for schizoaffective disorder. 61 54
15494707 2005
Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population. 54 61
15567076 2005
Association of the DTNBP1 locus with schizophrenia in a U.S. population. 61 54
15362017 2004
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. 61 54
15386212 2004
ProtocadherinX/Y, a candidate gene-pair for schizophrenia and schizoaffective disorder: a DHPLC investigation of genomic sequence. 54 61
15274028 2004
A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. 61 54
15121646 2004
Long-term observational comparison of risperidone and olanzapine in bipolar disorder. 54 61
15328900 2004
Clinical phenotypes associated with DISC1, a candidate gene for schizophrenia. 61 54
15184103 2004
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. 61 54
14744169 2004
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. 61 54
12140115 2002
NOTCH4 gene polymorphism and susceptibility to schizophrenia and schizoaffective disorder. 54 61
11239712 2001
[Levels and molecular heterogeneity of serotonin transporter protein in platelets of patients with different mental diseases: a comparative analysis with the use of monoclonal and polyclonal antibodies]. 54 61
11523428 2001
Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. 54 61
11060712 2000
Negative symptoms of familial schizophrenia breed true in unstable (vs. stable) cerebral-ventricle pedigrees. 54 61
9988837 1999
A genome-wide search for schizophrenia susceptibility genes. 61 54
9754621 1998
Neuroendocrine responsivity to clomipramine challenge test in neuroleptic naive psychotic patients before and after treatment with haloperidol. 54 61
19698552 1997
A comparison of cognitive profiles in schizophrenia and other psychiatric disorders. 61 54
8771446 1996
Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. 61 54
7944879 1994
Self-other differentiation among psychotic and conduct-disordered adolescents as measured by human figure drawings. 54 61
8483645 1993
Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome 11q in 112 Irish multiplex families. 61 54
8439241 1993
Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. 61 54
2255750 1990
The Effect of Child Sexual Abuse on Social Functioning in Schizophrenia Spectrum Disorders. 61
29884109 2021
Psychotropic-Induced Priapism in a Treatment-Refractory Patient: A Case Report. 61
31694449 2021
Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia. 61
33783399 2021
Current and emerging long-acting antipsychotics for the treatment of schizophrenia. 61
33775184 2021
Schizophrenia and Bartonella spp. Infection: A Pilot Case-Control Study. 61
33728987 2021
Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder. 61
33805007 2021
The effect of prednisolone on symptom severity in schizophrenia: A placebo-controlled, randomized controlled trial. 61
33711681 2021
Neural Processing of Repeated Emotional Scenes in Schizophrenia, Schizoaffective Disorder, and Bipolar Disorder. 61
33693875 2021

Variations for Schizoaffective Disorder

Expression for Schizoaffective Disorder

Search GEO for disease gene expression data for Schizoaffective Disorder.

Pathways for Schizoaffective Disorder

GO Terms for Schizoaffective Disorder

Cellular components related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.31 SLC6A4 SLC1A1 RGS4 PCDH11X NRXN1 NOTCH4
2 cell junction GO:0030054 9.91 SLC6A4 SLC1A1 NRXN1 HTR2A GABRB1 DTNBP1
3 integral component of plasma membrane GO:0005887 9.85 SLC6A4 SLC1A1 PCDH11X NRXN1 NOTCH4 HTR2A
4 dendrite GO:0030425 9.8 SLC1A1 HTR2A HTR1A GABRB1 DRD2 COMT
5 presynapse GO:0098793 9.76 SLC6A4 SLC1A1 NRXN1 HTR2A
6 dendritic spine GO:0043197 9.71 SLC1A1 DTNBP1 DRD2 COMT
7 GABA-ergic synapse GO:0098982 9.69 GABRB1 DRD3 DRD2
8 endocytic vesicle GO:0030139 9.65 NRXN1 DRD3 DRD2
9 integral component of presynaptic membrane GO:0099056 9.62 SLC6A4 NRXN1 HTR2A DRD2
10 integral component of postsynaptic membrane GO:0099055 9.61 SLC6A4 HTR2A DRD2
11 asymmetric synapse GO:0032279 9.52 SLC1A1 DTNBP1
12 axon GO:0030424 9.5 SLC1A1 HTR2A DTNBP1 DRD2 DISC1 COMT
13 synapse GO:0045202 9.32 SLC6A4 SLC1A1 NRXN1 HTR2A HTR1A GABRB1

Biological processes related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 PRL NRXN1 HTR2A HTR1A GABRB1 DRD3
2 cellular calcium ion homeostasis GO:0006874 9.83 HTR2A DRD3 DRD2
3 response to toxic substance GO:0009636 9.8 SLC6A4 GABRB1 DRD2
4 memory GO:0007613 9.79 SLC6A4 HTR2A BDNF
5 learning GO:0007612 9.77 NRXN1 DRD3 COMT
6 chemical synaptic transmission GO:0007268 9.77 SLC1A1 NRXN1 HTR2A HTR1A GABRB1
7 synapse assembly GO:0007416 9.76 NRXN1 DRD2 BDNF
8 social behavior GO:0035176 9.73 SLC6A4 NRXN1 DRD3
9 regulation of synaptic vesicle exocytosis GO:2000300 9.7 HTR2A DTNBP1 DRD2
10 response to cocaine GO:0042220 9.69 RGS4 DRD3 DRD2
11 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.66 DRD3 DRD2
12 vasoconstriction GO:0042310 9.66 SLC6A4 HTR1A
13 behavior GO:0007610 9.65 HTR2A HTR1A
14 negative regulation of cytosolic calcium ion concentration GO:0051481 9.64 DRD3 DRD2
15 positive regulation of renal sodium excretion GO:0035815 9.64 DRD3 DRD2
16 G protein-coupled receptor internalization GO:0002031 9.63 DRD3 DRD2
17 response to drug GO:0042493 9.63 SLC6A4 SLC1A1 HTR2A DRD3 DRD2 COMT
18 prepulse inhibition GO:0060134 9.62 DRD3 DRD2
19 synaptic transmission, dopaminergic GO:0001963 9.62 DRD3 DRD2
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 DRD3 DRD2
21 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.6 DRD3 DRD2
22 serotonin receptor signaling pathway GO:0007210 9.58 HTR2A HTR1A
23 response to morphine GO:0043278 9.58 RGS4 DRD3 DRD2
24 regulation of potassium ion transport GO:0043266 9.57 DRD3 DRD2
25 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.55 DRD3 DRD2
26 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.54 DRD3 DRD2
27 dopamine metabolic process GO:0042417 9.5 DRD3 DRD2 COMT
28 response to histamine GO:0034776 9.49 DRD3 DRD2
29 regulation of locomotion involved in locomotory behavior GO:0090325 9.48 DRD3 DRD2
30 negative regulation of dopamine receptor signaling pathway GO:0060160 9.46 RGS4 DRD2
31 acid secretion GO:0046717 9.43 DRD3 DRD2
32 behavioral response to cocaine GO:0048148 9.43 HTR2A DRD3 DRD2
33 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.13 HTR2A DRD3 DRD2
34 regulation of dopamine secretion GO:0014059 8.92 HTR2A DTNBP1 DRD3 DRD2

Molecular functions related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.43 HTR2A HTR1A GABRB1
2 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD3 DRD2
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.96 DRD3 DRD2
4 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Schizoaffective Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....